Advertisement

A protein kinase switch

Kinase inhibitors are plagued by a lack of specificity. Now in the 21 September Nature Bishop et al. tackle the problem by building on their earlier work, in which they modified the ATP-binding sites of Src-family tyrosine kinases to accept either nucleotide analogs or modified kinase inhibitors. In the new work the researchers mutate kinases from four distinct kinase families by replacing a bulky residue with a small residue. This change provides enough room for the binding of inhibitor analogs

By | October 2, 2000

Kinase inhibitors are plagued by a lack of specificity. Now in the 21 September Nature Bishop et al. tackle the problem by building on their earlier work, in which they modified the ATP-binding sites of Src-family tyrosine kinases to accept either nucleotide analogs or modified kinase inhibitors. In the new work the researchers mutate kinases from four distinct kinase families by replacing a bulky residue with a small residue. This change provides enough room for the binding of inhibitor analogs, which are larger than their parent inhibitors and thus do not inhibit wild-type kinases (Nature 2000, 407:395-401). The in vivo specificity is demonstrated using expression arrays. Most kinases contain a bulky residue analogous to the one mutated in this study, and thus should be amenable to the kinase-sensitization strategy.

Advertisement

Popular Now

  1. LabQuiz: What's Your Cell IQ?
    Sponsored Quiz LabQuiz: What's Your Cell IQ?

    Your body is made up of trillions of cells—but what do you really know about them? Take our lab quiz and determine your CIQ (cell identification quotient). 

  2. Genetic Connections Among Human Traits
  3. Antibiotics From Scratch
  4. Further Evidence that Life Might Have Started with RNA
Advertisement
R&D Systems
R&D Systems
Advertisement
Biosearch Technologies
illumina Corporate
illumina Corporate